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Abstract.
Background: S0931 is assessing recurrence-free survival in renal cell carcinoma (RCC) patients randomized to receive
everolimus (EVE) versus placebo for one year following nephrectomy. Due to a higher than expected dropout rate, we assessed
EVE trough levels in the adjuvant setting to evaluate the relationship between EVE exposure and probability of toxicity.
Methods: Patients received 10 mg daily EVE for nine 6-week cycles. Pre-dose whole blood samples were collected
pre-cycle 2 and pre-cycle 3 and analyzed for EVE. Patients with pre-cycle 2 and/or pre-cycle 3 EVE results were used in
the analysis. Patients were segregated into quartiles (Q) based on EVE levels and logistic regression was used to model the
most common adverse event outcomes using EVE trough as a predictor. Hazard and odds ratios were adjusted for age, BMI
and performance status.
∗Correspondence to: Timothy W. Synold, Pharm.D., City of
Hope National Medical Center, Department of Medical Oncol-
ogy and Therapeutic Research, 1500 E. Duarte Road, Duarte, CA
91010, USA. Tel.: +1 626 218 1110; Fax: +1 626 471 9376; E-mail:
tsynold@coh.org.
ISSN 2468-4562/19/$35.00 © 2019 – IOS Press and the authors. All rights reserved
This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC 4.0).
112 T.W. Synold et al. / Everolimus Exposure as a Predictor of Toxicity
Results: A total of 467 patients were included in this analysis. Quartiles normalized to an EVE dose of 10 mg/day were < 9.0,
9.0–12.9, 12.9–22.8, and > 22.8 ng/mL, respectively. EVE trough levels increased with increasing age (p< 0.001). Further-
more, EVE trough levels were higher in men than women (19.4 versus 15.4 ng/mL, p= 0.01). Risk of grade 2 + triglycerides
was increased in Q2 and Q3 vs Q1 (OR = 2.08; p= 0.02 and OR = 2.63; p= 0.002). Risk of grade 2 + rash was increased in
Q2 and Q4 vs Q1 (OR = 2.99; p= 0.01 and OR = 2.90; p= 0.02). There was also an increased risk of any grade 3 + tox in Q2
vs Q1 (OR = 1.71; p= 0.05).
Conclusions: We identified significant gender and age-related differences in EVE trough levels in patients receiving adjuvant
treatment for RCC. Furthermore, our analysis identified significant associations between EVE exposure and probability of
toxicity.
Keywords: Renal cell carcinoma, everolimus, pharmacokinetics, adjuvant chemotherapy, therapeutic drug monitoring
INTRODUCTION
The mTOR inhibitor everolimus (EVE) was origi-
nally developed for its immunosuppressant properties
in the prevention of rejection after solid-organ trans-
plantation. Based on positive effects on progression
free survival in the pivotal Phase III study [1], EVE
received FDA approval in 2009 for treatment of
patients with advanced RCC following treatment
failure with sunitinib or sorafenib. Although EVE
has improved outcomes in patients with advanced
RCC, its use is associated with several common
adverse events that represent a challenge to the
clinician [2]. Notably, metabolic disturbances such
as hyperglycemia and hyperlipidemia, along with
the mucositis/stomatitis and pneumonitis have been
commonly reported [3]. Rates of EVE treatment
interruption and dose reduction due to toxicity are
reported to be as high as 64% [4].
Because EVE has been shown to improve
progression-free survival in advanced RCC, it is
appropriate to study this active agent in the adjuvant
setting. EVE also has the advantage of oral dos-
ing, making it most suitable to chronic daily dosing.
However, chronic EVE dosing has not been previ-
ously studied in an adjuvant cancer population. Due
to the relatively high incidence of EVE-associated
adverse events, careful assessment of the tolerabil-
ity of chronic dosing is required. In April of 2011,
the Southwest Oncology Group initiated a random-
ized, double-blind, placebo controlled Phase III trial
evaluating one year of adjuvant EVE therapy in post-
nephrectomy RCC patients. In addition to evaluating
recurrence-free survival, a secondary objective is to
understand the frequency and severity of toxicity in
this population.
The published literature on EVE steady-state
pharmacokinetics and chronic toxicity has largely
been in the post-transplant setting in which it has
been co-administered with other immunosuppressant
drugs as part of triple-therapy rejection prophy-
laxis [5]. The applicability of this toxicity data to
the adjuvant renal carcinoma population is con-
founded by potential contribution of co-administered
immunosuppressants and other factors unique to the
post-transplant setting. The adjuvant renal carcinoma
setting involves a patient population with curative
potential. Therefore, mTOR inhibitor-associated side
effects with the potential for long-term implications,
such as hyperlipidemia and immunosuppression, are
of particular concern, especially with chronic daily
dosing [6].
In renal transplantation patients, a relationship has
been reported between EVE area-under-the-curve
(AUC) and both thrombocytopenia and metabolic
toxicities [5]. This has led to the routine clinical prac-
tice of therapeutic drug monitoring (TDM). Because
EVE trough levels have been shown to be closely cor-
related with the AUC, trough level monitoring has
become an acceptable surrogate measure of overall
everolimus exposure [7]. In the post-transplantation
setting, EVE trough levels are recommended to be
maintained in the desired range of 3 to 8 ng/mL
to optimize efficacy and decrease the incidence of
adverse reactions, but trough levels of up to 15
ng/mL are associated with manageable toxicity [6,
8]. Although the target exposure range for EVE has
not been established in cancer patients, a recently
published study of advanced cancer patients receiv-
ing 10 mg daily found that EVE trough levels above
26.3 ng/mL were associated with a 4-fold increased
risk of toxicity, while levels below 11.9 ng/mL were
associated with a 3-fold increased risk of progression
[9].
On the current SWOG 0931 study, steady-state
trough blood samples were prospectively collected
from patients during the first 2 cycles of therapy. The
goal of this analysis was to evaluate the relationship
between measured EVE exposure and the incidence
of the most common EVE-associated toxicities.
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A potential association between EVE trough levels
and disease free survival will also be explored once
the data are mature and the study is unblinded. It may
ultimately be possible to define an EVE target range
that can be applied in a TDM approach to minimize
the risk of toxicity and maximize the probability of
survival in the RCC adjuvant setting.
PATIENTS AND METHODS
Patients and treatment
Patients with histologically or pathologically con-
firmed RCC considered to be intermediate or high
risk and who had undergone full surgical resection
including removal of all positive lymph nodes were
eligible. Subjects were randomized to receive EVE
10 mg/day or placebo for nine 6-week cycles. Dose
reductions were allowed for toxicity and included 5
mg/day (Dose Level -1) and 5 mg every other day
(Dose Level -2). Once the dose was reduced, patients
continued on the same dose and no dose escalations
were allowed. Treatment was discontinued if EVE
was withheld for > 21 days for pneumonitis or > 28
days for any other reason.
Once EVE treatment was initiated, toxicity assess-
ments were performed weekly during the first cycle
and then at the start of each subsequent cycle. Weekly
toxicity assessments could be performed by phone
during the first cycle for weeks when a physical exam
was not required. Toxicity grading was performed
using the NCI Common Terminology Criteria for
Adverse Events (CTCAE) version 4.0.
For assessment of EVE trough levels, pre-dose
blood samples were collected pre-cycle 2 and pre-
cycle 3. Prior to their scheduled appointments,
patients were instructed not to take their daily EVE
dose until after their blood was drawn in the clinic.
Five milliliters of whole blood was collected in plastic
purple-top EDTA tubes and tubes were stored frozen
at –20◦C until subsequent batch analysis. Whole
blood concentrations of EVE were analyzed using
LC-MS/MS as previously described [10].
Statistical methods
Patients with pre-cycle 2 and/or pre-cycle 3 EVE
measurements were used in the analysis. When both
trough levels were available, the results were aver-
aged. Samples with an EVE concentration below the
lower limit of detection for the assay (0.25 ng/mL)
were excluded. Furthermore, samples where the EVE
dose at end of the previous cycle was reported to
be “0 mg” were excluded. Patients who were not
assessable for toxicity were also excluded. For each
time point, raw EVE measurements were normal-
ized to a dose 10 mg/day based on the steady-state
dose reported at end of the previous cycle. Patients
were segregated into quartiles (Q) based on EVE
levels and logistic regression was used to model
the following adverse event outcomes using EVE
trough as a predictor; any grade 3 + toxicity, grade
2 + hypertriglyceridemia, grade 2 + hyperglycemia,
grade 2 + oral mucositis, and grade 2 + rash (maculo-
papular, acneiform, or pustular). Cox proportional
hazards regression was used to assess time to prema-
ture stopping of EVE. Hazard and odds ratios were
adjusted for age, BMI and performance status.
RESULTS
Everolimus pharmacokinetics
This study reached its accrual goal and was closed
to enrollment in September 2016 with 1545 total
patients, 775 randomized to the EVE arm. A total
of 467 patients had pre-cycle 2 and/or pre-cycle 3
EVE trough measurement and were included in this
analysis. The median EVE trough was 12.8 ng/mL
(range 3.1, 75.6) per 10 mg dose. EVE trough quar-
tile ranges are summarized in Table 1. Of the 467
patients, 129 (28%) had their doses reduced prior to
the pre-cycle 2 and/or pre-cycle 3 EVE trough sam-
ple. Quartile ranges normalized to an EVE dose of 10
mg/day were < 9.0, 9.0–12.9, 12.9–22.8, and > 22.8
ng/mL, respectively.
The clinical characteristics of the patients included
in this sub-study were compared with those who were
not included due to missing EVE trough levels and no
notable differences were found. Table 2 summarizes
EVE trough results by key demographic features. As
shown in the table and depicted in Fig. 1A, there was
a significant positive association between increasing
age and EVE trough levels (p< 0.001). EVE trough
concentrations normalized to a dose of 10 mg/day
Table 1
EVE average trough quartiles normalized to a
dose of 10 mg/day
Quartile No. of Subjects Range
(ng/mL per 10 mg)
1 117 <9.0
2 117 9.0–12.9
3 116 12.9–22.8
4 117 >22.8
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Table 2
Patient characteristics from the everolimus arm with averaged pre-cycle 2 and pre-cycle
3 EVE troughs normalized to a dose of 10 mg/day
Baseline Patient Characteristics N = 467 ADJUSTEDa p-valueb
(ng/mL per 10 mg)
(mean, range)
Age under 52 31% 14.4 (1.7, 70.5) <0.001
52–61 33% 18.4 (0.5, 60.7)
62 and over 36% 20.8 (0.3, 75.6)
Race White 93 % 18.1 (0.3, 75.6) 0.42
Other 7 % 16.4 (5.0, 60.7)
Gender Male 69 % 19.2 (1.8, 75.6) 0.01
Female 31 % 15.4 (0.3, 70.5)
BMI Normal 18 % 18.5 (0.5, 61.5) 0.71
Overweight 35 % 18.0 (3.1, 65.0)
Obese 47 % 17.8 (0.3, 75.6)
Risk Group Intermediate high risk 44 % 17.3 (0.3, 70.5) 0.84
Very high risk 56 % 18.5 (1.7, 75.6)
Histology Clear cell 81 % 18.0 (0.3, 75.6) 0.98
Non-clear cell 19 % 18.0 (1.7, 57.1)
Performance Status 0 79 % 17.8 (0.5, 70.5) 0.47
1 21 % 18.7 (0.3, 75.6)
Extent of surgical resection Radical nephrectomy 91 % 17.9 (0.3, 75.6) 0.37
Partial nephrectomy 9 % 19.1 (2.9, 50.1)
Invasion of renal vein Yes 34 % 17.6 (1.8, 61.5) 0.93c
No 58 % 18.4 (0.3, 75.6)
Unknown 8 % 16.5 (5.3, 55.9)
Stage pTX, pT0, pT1a <1 % 14.2 (3.7, 23.1) 0.09d
pT1b 8 % 15.0 (4.2, 47.4)
pT2a 11 % 16.4 (0.3, 40.6)
pT2b 8 % 17.2 (4.9, 57.1)
pT3a 54 % 18.9 (0.5, 75.6)
pT3an 10 % 17.6 (2.9, 53.3)
pT3b-c 6 % 18.1 (1.8, 51.0)
pT4 2 % 20.0 (7.6, 55.6)
Regional lymph nodes pN0 31 % 19.2 (3.1, 68.7) 0.15e
pNX 61 % 17.6 (0.3, 75.6)
pN+ 8 % 16.3 (1.7, 61.5)
Histologic grade GX 2 % 16.9 (1.7, 51.7) 0.61 f
G1 2 % 13.3 (0.5, 38.7)
G2 24 % 18.0 (0.3, 70.5)
G3-4 72 % 18.1 (1.8, 75.6)
aaveraged pre-cycle 2 and pre-cycle 3 samples, adjusted for EVE dose at time of collection. bKruskal-Wallis
test. cpatients with unknown invasion of renal vein were excluded from this test. dpatients with pTX, pT0,
pT1a were excluded from this test, remaining patients were grouped into categories: pT1/pT2 and pT3/pT4.
epN0 combined with pNX in this test. f patients with GX were excluded from this test.
in patients under 52 years, 52–61 years and over 62
years were 14.4 (1.7, 70.5), 18.4 (0.5, 60.7), and 20.8
(0.3, 75.6) ng/mL, respectively. Furthermore, men
had significantly higher normalized EVE trough lev-
els than women (19.4 versus 15.4 ng/mL, p= 0.01).
There was also a trend towards increasing EVE trough
with increasing disease stage, but this was not signif-
icant (p= 0.09)
EVE trough-toxicity analyses
The rates for the most common EVE-associated
adverse events are summarized in Table 3.
The percentage of patients with any grade
3 + toxicity, grade 2 + hypertriglyceridemia, grade
2 + hyperglycemia, grade 2 + oral mucositis, and
grade 2 + rash were 41% (193/467), 30% (141/467),
14% (64/467), 33% (152/467), and 13% (62/467),
respectively. The percentage of patients prematurely
stopping EVE for any reason was 39% (172/441).
Table 3 also summarizes the EVE trough quartiles
according to risk of individual adverse events and
premature stopping of EVE. As shown in the table
and Fig. 2. The risk of grade 2 + hypertriglyceridemia
was significantly increased in Q2 and Q3 vs
Q1 (OR = 2.08; p= 0.02 and OR = 2.63; p= 0.002).
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Fig. 1. Mean EVE trough versus age (panel A) and gender (panel B). Symbols are the mean EVE trough values normalized to a dose of 10
mg/day. Bars indicate the 95% confidence intervals.
Table 3
Association of EVE troughs and adverse events and premature stopping
Reference group = Q1
Logistic Regression Outcome Quartile OR (95% CI)* p-value∗
Any toxicity Grade 3 + 1 REF REF
Event rate: 41% (193/467) 2 1.71 (1.01, 2.92) 0.05
Chi-square (df = 3) test
p= 0.004
3 1.51 (0.88, 2.60) 0.13
4 0.68 (0.39, 1.20) 0.18
Hypertriglyceridemia Grade 2 + 1 REF REF
Event rate: 30% (141/467) 2 2.08 (1.40, 3.78) 0.02
Chi-square (df = 3) test
p= 0.007
3 2.63 (0.45, 4.78) 0.002
4 1.38 (0.74, 2.59) 0.31
Hyperglycemia Grade 2 + 1 REF REF
Event rate: 14% (64/467) 2 1.32 (0.61, 2.85) 0.49
Chi-square (df = 3) test p= 0.53 3 0.73 (0.31, 1.70) 0.47
4 1.12 (0.50, 2.50) 0.79
Oral mucositis Grade 2 + 1 REF REF
Event rate: 33% (152/467) 2 0.99 (0.58, 1.71) 0.99
Chi-square (df = 3) test p= 0.87 3 0.84 (0.48, 1.46) 0.53
4 0.85 (0.49, 1.48) 0.56
Combined rash Grade 2+
(maculo-papular, acneiform, pustular)
1 REF REF
2 2.99 (1.26, 7.09) 0.01
Event rate: 13% (62/467) 3 1.77 (7.0, 4.48) 0.23
Chi-square (df = 3) test p= 0.05 4 2.90 (1.21, 6.97) 0.02
PH regression Outcome Quartile Hazard Ratio (95% CI)* p-value*
Premature stopping of EVEa 1 REF REF
Event rate: 39% (172/441) 2 1.06 (0.68, 1.65) 0.79
Chi-square (df = 3) test p= 0.48 3 1.03 (0.65, 1.61) 0.91
4 1.34 (0.87, 2.06) 0.18
aPercentage of patients prematurely stopping EVE for any reason excepta death or progression.
Furthermore, the risk of grade 2 + rash was signif-
icantly increased in Q2 and Q4 vs Q1 (OR = 2.99;
p= 0.01 and OR = 2.90; p= 0.02). There was
also an increased risk of any grade 3 + tox in
Q2 vs Q1 (OR = 1.71; p= 0.05). The proportion
of patients with adverse event-related discontin-
116 T.W. Synold et al. / Everolimus Exposure as a Predictor of Toxicity
uations was similar across EVE trough quartiles
(p= 0.48).
DISCUSSION
Due to the advances made in the treatment of
metastatic RCC using tyrosine kinase inhibitors,
there have been multiple trials conducted to deter-
mine whether these active drugs can improve survival
in the adjuvant setting. However, results of these stud-
ies to date have been mixed. The S-TRAC trial found
that adjuvant sunitinib resulted in longer disease-
free survival compared placebo in high-risk clear
cell RCC [11], while the ASSURE trial showed no
survival benefit to adjuvant treatment with either
sunitinib or sorafenib relative to placebo [12]. Fur-
thermore, while a placebo-controlled randomized
study of adjuvant pazopanib (PROTECT) showed
some improvement in disease free survival, it failed
to meet its primary endpoint [13]. Therefore, whether
there is an overall benefit to adjuvant VEGF-directed
therapy, and if so, who would be most likely to benefit
remain open questions.
A common theme among all of the adjuvant RCC
trials to date has been the high frequency of bother-
some toxicity resulting in treatment discontinuation
on the active treatment arms. For example, the per-
centage of patients who discontinued sunitinib due to
toxicity was 28.1% on the S-TRAC trial [11] and 44%
on the ASSURE study [12]. The rate of pazopanib dis-
continuation because of AEs on PROTECT was 35%
and 39% in the 800 mg and 600 mg dose cohorts,
respectively [13]. On the current S0931 study, 39%
of the patients on the active treatment arm prema-
turely discontinued EVE. Interestingly, only 13% of
patients receiving EVE on the pivotal Phase III trial
for metastatic RCC discontinued treatment due to
adverse events [1], consistent with the observation
that patients are generally less tolerant of toxicities
in the adjuvant setting [11]. It is intriguing to won-
der whether the survival outcome differences seen
with S-TRACT and ASSURE might be due to the
ability of patients to stay on the drug longer in the
former compared to the later. Furthermore, a correla-
tion was observed between higher pazopanib trough
concentrations and longer DFS on PROTECT. Taken
together, these results suggest that higher serum drug
concentrations may be associated with greater clin-
ical benefit. It also leads to the question of whether
there is a way to improve the tolerability and efficacy
of these TKIs on an individual basis guided by TDM.
Dose individualization of EVE based on measured
trough levels is an established clinical practice in
solid organ transplant patients, with the target thera-
peutic widow defined as 3–8 ng/mL. More recently,
investigations in patients with advanced solid tumors,
including some with metastatic RCC, have reported
significant associations between EVE trough levels
and both toxicity and progression free survival [4, 9]
For example, Deppenweiler et al. [9] reported that
patients with EVE trough levels > 26.3 ng/mL had a
4-fold increased risk of toxicity, while patients with
trough levels < 11.9 ng/mL had a 3-fold increased risk
of progression. Another group of investigators [14]
found that advanced RCC patients who discontin-
ued treatment due to toxicity had significantly higher
EVE trough levels compared to those who did not
(27.6 vs 15.7 ng/mL), and the patients who stopped
treatment due to adverse events had a short time to
treatment failure. Based on the published evidence
supporting the existence of EVE exposure-toxicity
and exposure-response relationships, it seems likely
that there is an optimal therapeutic window for RCC
patients that can be targeted to minimize the risk
of toxicity and maximize the likelihood for a good
clinical outcome.
In the current study, we attempted to identify
relationships between EVE trough levels and the
most common toxicities. Although we found signif-
icant associations between increasing EVE trough
levels and the risk of hypertriglyceridemia, skin tox-
icity, and any grade 3 + toxicity, these associations
were not consistent across all quartiles. For exam-
ple, the increased risk of hypertriglyceridemia was
only significant between Q2 and Q3 compared to Q1.
The highest EVE quartile was not associated with
an increased risk of hypertriglyceridemia. However,
when the data are presented graphically (i.e. Fig. 2),
an overall trend towards increasing risk of toxicity
can be seen. Although this data set includes a large
number of subjects, a major limitation is that EVE
trough measurements were only performed once or
twice per subject during the first 13 weeks of a 52
week treatment period. Furthermore, dose normaliza-
tion of EVE trough levels could have introduced bias
since the most common reason for dose reduction was
for toxicity. Finally, factors such as non-compliance,
inaccurate sample collection times, and intra-subject
pharmacokinetic variability are potential confound-
ing variables that could have affected our estimate
of true EVE trough values. An ideal study would
include more frequent trough level measurements
over a longer period of time, particularly close in time
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Fig. 2. Risk of hypertriglyceridemia (panel A) and combined skin rash (panel B) by EVE trough quartile ranges.
to the occurrence of adverse events. However, this is
not practical in a large multicenter Phase 3 trial such
as this one.
Despite the limited associations seen between EVE
trough levels and toxicity, we were able to identify age
and gender-related differences in EVE pharmacoki-
netics. Men were found to have higher EVE tough
levels than women, while trough levels also increased
with increasing age independent of gender. Previ-
ous pharmacokinetic analyses have failed to identify
associations between age or gender and EVE dispo-
sition, although most of these studies have been in
the solid organ transplant setting. Interestingly, the
study of Thiery-Vuillemin et al. [15] in patients with
advanced RCC, reported similar effects of age and
gender on EVE trough levels as the ones reported
here. Also, a population-based pharmacokinetic anal-
ysis of EVE in RCC patients [14] found a trend
towards lower clearance in older patients, which is
consistent with increasing trough levels with age. The
mechanisms of these interactions and their potential
significance are yet to be determined.
The results presented here add to the growing body
of literature pointing to a relationship between mea-
sured EVE exposure and toxicity. Additional analyses
once the study is unblinded will assess whether there
is an association between EVE trough levels and
survival. Regardless of the outcome of the future
analyses, sufficient evidence already exists to support
a prospective study comparing fixed dose to dose-
individualized EVE in advanced RCC patients. While
questions remain regarding the optimal EVE thera-
peutic window and the preferred frequency for TDM,
based on the current data and previously reports [9,
14, 15], targeting trough levels between 15 and 20
ng/mL could potentially decrease the risk of toxicity
leading to treatment discontinuation and increase the
likelihood of a good outcome.
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